Anumigilimab is under clinical development by CSL and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Anumigilimab’s likelihood of approval (LoA) and phase transition for Palmoplantar Pustulosis took place on 07 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Anumigilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Anumigilimab overview

Anumigilimab (CSL324) is under development for the treatment of Coronavirus disease 2019 (COVID-19), cancer, inflammatory diseases associated with neutrophil infiltration including chronic obstructive pulmonary disease (COPD), rheumatoid arthritis,  neutrophilic dermatoses, hidradenitis suppurativa and palmoplantar pustulosis. It is administered intravenously. It is a recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor.

CSL overview

CSL discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.

Quick View Anumigilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Anumigilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Dermatology
  • Immunology
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: CSL
  • Originator: CSL Innovation and MuriGen Therapeutics
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.